血浆及粪便中肿瘤M2型丙酮酸激酶检测在结肠癌诊断中的价值

Tumor type M2 pyruvate kinase in feces and plasma in diagnosis of colon cancer

  • 摘要: 目的 评估血浆及粪便中肿瘤M2型丙酮酸激酶(TUM2-PK)作为肿瘤标志物在结肠癌患者临床诊疗中的应用价值。方法 用酶联免疫吸附试验(ELISA)检测34例结肠癌患者以及20名健康体检者的血浆及粪便中的TUM2-PK,进行比较分析。结果 结肠癌患者血浆以及粪便中TUM2-PK水平显著高于健康对照组(P<0.01),其总体敏感性分别为65.0%,82%,随着肿瘤病程进展,中晚期患者血浆以及粪便中TUM2-PK水平(77%,100%)明显高于早期患者(44%,84%,P<0.01)。结论 血浆及粪便TUM2-PK测定可提高对结肠癌诊断的有效性,可作为一种常规的辅助诊断方法。

     

    Abstract: Objective To evaluate the value of tumor type M2 pyruvate kinase(TU M2-PK)in plasma and feces in diagnosis of colon cancer. Methods Peripheral blood and feces were collected from 34 colon cancer patients and 20 healthy persons,respectively.The levels of TU M2-PK in plasms and feces were measured by ELISA. Results The levels of TU M2-PK in plasma and feces from with colon cancer were significantly higher than those from controls(P<0.01).The cutoff value was established at 15U/mL for plasma,4.0U/mL for TU M2-PK in feces.The sensitivity to TU M2-PK in plasma and feces was 65%and 82%,respectively.The levels of TU M2-PK in plasma and feces increased significantly with the progression of colon cancer.The sensitivity to Duke’s A and D increased from 44%to 84%in plasma TU M2-PK,and from 77%to 100%in stool TU M2-PK. Conclusion TU M2-PK level in plasma and feces can be used as a valuable marker in diagnosis of colon cancer.

     

/

返回文章
返回